Top Diseases Stories


Comment & Analysis »

GlobalData Healthcare

PARP inhibitor market in ovarian cancer set for a showdown

AstraZeneca’s poly(ADP-ribose) polymerase (PARP) inhibitor, Lynparza (olaparib), had enjoyed two years alone on the ovarian cancer market without direct competition until Clovis Oncology’s...

PARP inhibitor market in ovarian cancer set for a showdown
GlobalData Healthcare

Promising preliminary data from Phase II study encourages Axovant to expand trial

Promising preliminary data from Phase II study encourages Axovant to expand trial
GlobalData Healthcare

Merck’s Verubecestat marks a new era for Alzheimer’s treatment

Merck’s Verubecestat marks a new era for Alzheimer’s treatment

Pharma Technology Focus – Issue 50

Pharma Technology Focus – Issue 50
 

July's top stories: GBT's Phase II1 trial GBT440, Merck's Phase III trial ONCEMRK of Isentress

July's top stories: GBT's Phase II1 trial GBT440, Merck's Phase III trial ONCEMRK of Isentress

Company Releases »

ePAT Automated Lab Reactor Optimised for 24/7 Data Capture

SYSTAG Systems Technik
ePAT Automated Lab Reactor Optimised for 24/7 Data Capture

Optimising Development Resources for Efficient Product Development

SYSTAG Systems Technik
Optimising Development Resources for Efficient Product Development

Orthotopic and metastasis models for preclinical efficacy testing of novel cancer drugs

Pharmatest Services Orthotopic and metastasis models for preclinical efficacy testing of novel cancer drugs

Research Models to Evaluate Drug Candidate Efficacy

Pharmatest Services
Research Models to Evaluate Drug Candidate Efficacy

Custom Monoclonal and Polyclonal Antibody Development

ImmunoPrecise Antibodies Custom Monoclonal and Polyclonal Antibody Development

Diseases Insights »

Companies »